Sunshine Biopharma Inc
SBFM
NASDAQ
Biotechnology
$1.15
USD
-0.05 (-4.17%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $2.85M
Volume 102.0K
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Fort Lauderdale, Florida and currently employs 50 full-time employees. The company went IPO on 2008-08-15. The firm has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The firm operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.
CEO
Dr. Steve Slilaty
HQ
FORT LAUDERDALE, FLORIDA, US
Founded
2008
Employees
52
Quantli Score
8.4
Outperform
Fin. Health
8.1
Profitability
7.6
Growth
9.0
Cash-Flow Q.
8.8
Key Metrics
6 metrics our research team weighs before forming a view on SBFM.
Based on Quantli research · SEC filings · as of Q1 2026
METRIC
VALUE
CHANGE
TREND (3Y)
Revenue Growth (TTM)
-2.0%
-37.6 pp
Gross Margin (TTM)
33.0%
+2.5 pp
Operating Margin (TTM)
-17.8%
-2.1 pp
Net Margin (TTM)
-17.0%
-3.1 pp
ROE (TTM)
-28.1%
-5.9 pp
Free Cash Flow (TTM)
$-5.86M
—
Financial Snapshot
Revenue
$35.49M
-2.0%
YoY
Gross Margin
33%
TTM
+8.2%
YoY
Net Income
$-6.04M
-20.1%
YoY
Operating Cash Flow
$-5.69M
+48.4%
YoY
Key Statistics
Open
$1.18
Previous Close
$1.20
Day Range
$1.14 - $1.21
52 Week Range
$1.10 - $24.30
Volume
102.0K
Average Volume (10 Days)
1.6M
Dividend Yield
—
Valuation Measurement
Market Cap
$2.85M
P/E Ratio (TTM)
—
P/S Ratio (TTM)
0.08
Price / Book
0.13
Financial Highlights
Profit Margin
-17.0%
Return on Assets
-21.6%
Return on Equity
-28.1%
Revenue (TTM)
$35.49M
Net Income (TTM)
$-6.04M
Diluted EPS (TTM)
-$12.69
Total Cash (MRQ)
$6.91M
Levered FCF (TTM)
$-5.86M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
